Search Results for “cancer” – Page 164 – media

Bay Area’s ARMO BioSciences Banks $67 Million From Big Name Investors Like Celgene (CELG) And Google (GOOG)

ARMO BioSciences, Inc., a late-stage immuno-oncology company, today announced the successful completion of a $67 million Series C-1 private financing. The Series C-1 proceeds will be used to initiate phase 2/3 studies with ARMO's lead immunotherapy agent AM0010 in non-small cell lung cancer(NSCLC) and renal cell cancer and to support an ongoing pivotal phase 3 clinical trial in advanced pancreatic cancer.
- Source: biospace
- 523
- September 13, 2017
immunotherapy Market Views NSCLC pancreatic renal Series
GSK Exercises Option over SPEAR T-cell Therapy Program Targeting NY-ESO

Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that GlaxoSmithKline plc (LSE:GSK) (NYSE:GSK) has exercised its option under a collaboration and license agreement signed in 2014 to exclusively license the right to research, develop, and commercialize Adaptimmune’s NY-ESO SPEAR T-cell therapy program. Further details will be provided in a conference call scheduled for 8:30 AM EDT this morning; dial-in and webcast details are provided below.
- Source: Globenewswire
- 3,266
- September 11, 2017
cancer Company Insight T-cell
Merck KGaA Plans Consumer Healthcare Sale After Strategic Review

Germany's Merck KGaA is looking to sell its $1 billion consumer healthcare unit after a group-wide strategic review.
- Source: thestreet
- 598
- September 7, 2017
Company Insight healthcare Market Views Merck
Takeda and Noile-Immune Biotech Collaborate to Advance Next Generation CAR-T Cell Therapy Effective for Solid Tumors

A collaboration to develop next generation chimeric antigen receptor T cell therapy (CAR-T) (RELATED: Kite begins EU trial of CAR–T therapy) was announced by Takeda Pharmaceutical Company Limited (TSE: 4502) and Noile-Immune Biotech Inc..
- Source: Takeda
- 866
- September 6, 2017
antigen CAR–T Market Views receptor therapy
FDA Grants Priority Review for Genentech’s Gazyva in Previously Untreated Follicular Lymphoma

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has accepted the company’s supplemental Biologics License Application (sBLA) and granted Priority Review for Gazyva® (obinutuzumab) in combination with chemotherapy followed by Gazyva alone for people with previously untreated follicular lymphoma, one of the most common blood cancers among adults. Follicular lymphoma, a slow-growing (indolent) form of non-Hodgkin’s lymphoma, is incurable and characterized by cycles of remission and relapse.
- Source: biospace
- 559
- September 5, 2017
cancer FDA follicular lymphoma New Approvals sBLA
MedGenome raises $30m for biomarker discovery program

MedGenomeGenomics research and diagnostics company MedGenome said today that it closed a $30 million Series C round led by Sequoia India and Sofina. Zodius Capital, the co-founder & former CEO of Infosys, Kris Gopalakrishnan, and former Cognizant CEO Lakshmi Narayanan also participated in the round.
- Source: drugdeliverybusiness
- 608
- August 30, 2017
genetic immunotherapy Market Views Series
“Body-on-a-chip” device screens human heart cells for drug toxicity

A "body-on-a-chip" device that can evaluate the side-effects of drugs on human cells has been developed by researchers at Kyoto University's Institute for Integrated Cell-Material Sciences, according to a study published today in the Royal Society of Chemistry Advances.
- Source: drugdeliverybusiness
- 585
- August 29, 2017
doxorubicin Researches side-effect toxicity
Takeda partners to develop novel oncology therapies

Collaboration on an oncology drug discovery program was inked between Takeda Pharmaceutical, through its subsidiary Millennium Pharmaceuticals, and Molecular Templates.
- Source: drugdeliverybusiness
- 829
- August 28, 2017
Company Insight Market Views oncology therapy
Merck sees promise in Macrophage Pharma

Merck Ventures has become the latest group to invest in Macrophage Pharma and take a position on the UK biotech’s board of directors.
- Source: pharmatimes
- 630
- August 25, 2017
Clinical Market Views Merck
US regulators wave through Pfizer’s leukaemia drug

Pfizer’s Besponsa has been approved by the US Food and Drug Administration (FDA). It's the first and only CD22-directed antibody-drug conjugate indicated to treat relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (ALL).
- Source: pharmatimes
- 1,029
- August 21, 2017
ALL antibody Company Insight FDA New Approvals

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.